Neurología : publicación oficial de la Sociedad Española de Neurología
-
Multicenter Study
[Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
In this article we report adherence data from the first 2 years in a subset of patients from the Global Adherence Project (GAP; n=2,648) in Spain. ⋯ Adherence remained high over the first 2 years of the study. It was highest with Avonex®, being significant on first assessment, after 40.5 months of therapy, on average compared with other DMTs and at year 1 compared with Rebif®22.